News & Updates

Upadacitinib superior to dupilumab in patients with moderate-to-severe AD

13 Oct 2024 by

Treatment with upadacitinib demonstrated superior efficacy in achieving near-complete skin clearance and little to no itch at 16 weeks compared with dupilumab among adolescents and adults with moderate-to-severe atopic dermatitis (AD), according to the LEVEL UP study presented at EADV 2024.

Upadacitinib superior to dupilumab in patients with moderate-to-severe AD

13 Oct 2024

Hidradenitis suppurativa patients get durable benefit with bimekizumab

12 Oct 2024 by

The interleukin-17 blocker bimekizumab delivers sustained clinical benefits lasting up to 2 years for patients with moderate-to-severe hidradenitis suppurativa, as reported in a late-breaking presentation at EADV 2024.

Hidradenitis suppurativa patients get durable benefit with bimekizumab

12 Oct 2024

Risankizumab eases symptoms in nonpustular palmoplantar psoriasis

12 Oct 2024 by

In patients with nonpustular palmoplantar psoriasis (nPPP), treatment with risankizumab relieves disease symptoms, such as skin pain in palms or soles of feet, by week 16, as shown by the results of a post hoc analysis of the phase IIIb IMMprint study. These improvements persist up to week 52.

Risankizumab eases symptoms in nonpustular palmoplantar psoriasis

12 Oct 2024

As-needed ruxolitinib in children with AD: Disease control stable through 52 weeks

12 Oct 2024 by

As-needed application of ruxolitinib cream, a topically administered selective Janus kinase 1/2 inhibitor, resulted in long-term safety and disease control in children aged 2–11 years with mild-to-moderate atopic dermatitis (AD), according to updated results of the phase III TRuE-AD3 trial presented at EADV 2024.

As-needed ruxolitinib in children with AD: Disease control stable through 52 weeks

12 Oct 2024

Long-term secukinumab safe, effective in kids with plaque psoriasis

11 Oct 2024 by

Long-term treatment with secukinumab, either at low or high dose, results in sustained efficacy and better health-related quality of life up to 4 years in children and adolescents with moderate-to-severe chronic plaque psoriasis, as shown in a phase III study presented at EADV 2024.

Long-term secukinumab safe, effective in kids with plaque psoriasis

11 Oct 2024

Original New Drug Application Approvals by US FDA (1-15 September 2024)

09 Oct 2024

New drug applications approved by US FDA as of 1-15 September 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (1-15 September 2024)

09 Oct 2024

Subcuticular vs horizontal mattress suture: Which is preferable for wound closure?

03 Oct 2024

In the closure of linear wounds of the trunk and extremities, running subcuticular (SQ) suturing technique is preferred by patients and evaluators alike over running horizontal mattress (HM) in terms of aesthetic outcome, reports a recent study.

Subcuticular vs horizontal mattress suture: Which is preferable for wound closure?

03 Oct 2024

Roflumilast holds therapeutic potential for severe recurrent aphthous stomatitis

30 Sep 2024

In the treatment of severe recurrent aphthous stomatitis, roflumilast appears to reduce the number of flare-ups and ulcers, their duration, and ulcer-related symptoms, according to a study.

Roflumilast holds therapeutic potential for severe recurrent aphthous stomatitis

30 Sep 2024

Handheld skin analysis device delivers reliable skin age, health readings

27 Sep 2024 by

A novel handheld device can measure age-related skin parameters, including facial age, wrinkles, and skin evenness, with an accuracy that is similar to that of other well-established skin analysis devices, as reported in a study.

Handheld skin analysis device delivers reliable skin age, health readings

27 Sep 2024

RZV lowers herpes zoster risk in older adults

25 Sep 2024 by

The use of a recombinant zoster vaccine (RZV) significantly lowers the risk of developing herpes zoster in older adults aged ≥65 years compared with placebo, according to a study presented at WONCA 2024.

RZV lowers herpes zoster risk in older adults

25 Sep 2024

News & Updates

Filter by Specialty:

Specialty:

Upadacitinib superior to dupilumab in patients with moderate-to-severe AD

Upadacitinib superior to dupilumab in patients with moderate-to-severe AD

Hidradenitis suppurativa patients get durable benefit with bimekizumab

Hidradenitis suppurativa patients get durable benefit with bimekizumab

Risankizumab eases symptoms in nonpustular palmoplantar psoriasis

Risankizumab eases symptoms in nonpustular palmoplantar psoriasis

As-needed ruxolitinib in children with AD: Disease control stable through 52 weeks

As-needed ruxolitinib in children with AD: Disease control stable through 52 weeks

Long-term secukinumab safe, effective in kids with plaque psoriasis

Long-term secukinumab safe, effective in kids with plaque psoriasis

Original New Drug Application Approvals by US FDA (1-15 September 2024)

Original New Drug Application Approvals by US FDA (1-15 September 2024)

Subcuticular vs horizontal mattress suture: Which is preferable for wound closure?

Subcuticular vs horizontal mattress suture: Which is preferable for wound closure?

Roflumilast holds therapeutic potential for severe recurrent aphthous stomatitis

Roflumilast holds therapeutic potential for severe recurrent aphthous stomatitis

Handheld skin analysis device delivers reliable skin age, health readings

Handheld skin analysis device delivers reliable skin age, health readings

RZV lowers herpes zoster risk in older adults

RZV lowers herpes zoster risk in older adults